We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ULTMF market cap is 0. The company's latest EPS is NOK and P/E is N/A.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -66.22M | -124.15M | -163.83M | -183.63M | -215.74M |
| Net Income | -61.17M | -120.55M | -164.72M | -167.79M | -189.24M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Assets | 478.04M | 529.72M | 655.54M | 509.67M | 349.04M |
| Total Liabilities | 33.41M | 41.34M | 62.39M | 60.32M | 69.65M |
| Total Equity | 444.63M | 488.38M | 593.15M | 449.35M | 279.39M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Operating | -62.99M | -108.22M | -125.83M | -167.7M | -189.83M |
| Investing | 4.32M | -737k | 2.98M | 8.69M | 14.03M |
| Financing | 343M | 151.02M | 259.96M | 3.58M | -1.85M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 34.41M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Ultimovacs ASA (CE) |
| Address |
ullernchausseen 64 oslo 0379 |
| Website | https://www.ultimovacs.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
